Seer, Inc. Announces Leave of Its President and Chief Operating Officer, Omead Ostadan
October 13, 2021 at 04:05 pm EDT
Share
On October 13, 2021, Seer, Inc. announced that its President and Chief Operating Officer, Omead Ostadan, will be taking a leave of absence as an officer of the Company for personal reasons, beginning on November 20, 2021 and lasting approximately three months. In connection with the leave of absence, the Company and Mr. Ostadan entered into a Leave of Absence Agreement (the “Leave Agreement”), which provides for the suspension of Mr. Ostadan’s salary and vesting of equity awards during the leave of absence and the proration of Mr. Ostadan’s bonus opportunity.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
